Keywords: ABC; ATP-binding cassette transporters; ADSL; Adenylosuccinate Lyase; ALL; Acute Lymphoblastic Leukemia; ARID5B; AT-rich interaction domain 5B; B-ALL; B-Cell Acute Lymphoblastic Leukemia; BCR-ABL1; Breakpoint Cluster Region-ABelson murine Leukemia viral o
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Acute lymphoblastic leukemia; genomics; next-generation sequencing; tyrosine kinase inhibitors; BCR-ABL1; BCR-ABL1-like; Ph-like; MEF2D; ZNF384; DUX4; ERG;
Keywords: Adverse events; Algorithms; BCR-ABL1; Fluid retention; Tyrosine kinase inhibitor;
Keywords: BCR-ABL1; Molecular monitoring; Treatment response; Response kinetics;
Keywords: BCR-ABL1; Chronic myeloid leukemia; Dose intensity; Philadelphia chromosome; Ponatinib; Tyrosine kinase inhibitor;
Keywords: BCR-ABL1; Outcome; Prognosis; Resistance; Response
Keywords: Chronic myeloid leukemia; Tyrosine kinase inhibitor; Hematopoietic stem cell transplant; BCR-ABL1;
Keywords: NGS; CML; ALL; BCR-ABL1; Tyrosine kinase domain; TKI;
Keywords: Acquired resistance; BCR-ABL1; Kinase domain mutation; Tyrosine kinase inhibitor; T315I
Keywords: BCR-ABL1; CML; Conditional survival; Nomogram; Prognosis;
Keywords: BCR-ABL1; Clonogenic assay; Colony; Minimal residual disease; Tyrosine kinase inhibitor;
Keywords: Chronic myeloid leukaemia; BCR-ABL1; molecular monitoring; Standardisation
CircBA9.3 supports the survival of leukaemic cells by up-regulating c-ABL1 or BCR-ABL1 protein levels
Keywords: Chronic myelogenous leukaemia; BCR-ABL1; Circular RNA; Proliferation; Drug resistance;
Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring
Keywords: BCR-ABL1; Chronic myeloid leukemia; Molecular monitoring; Variant;
Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec
Keywords: BCR-ABL1; CML; Generic imatinib; Outcome; Response;
Biologie moléculaire de la leucémie myéloïde chronique : dernières avancées
Keywords: BCR-ABL1; inhibiteurs de tyrosine kinase; Leucémie myéloïde chronique; suivi moléculaire; BCR-ABL1; tyrosine kinase inhibitors; Chronic myeloid leukemia; molecular monitoring;
Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors
Keywords: Chronic myeloid leukemia (CML); Tyrosine kinase inhibitor (TKI); BCR-ABL1; Treatment-free remission (TFR); Drug resistance; Mutation;
Aberrant activation-induced cytidine deaminase expression in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia
Keywords: Activation-induced cytidine deaminase; Acute lymphoblastic leukemia; Philadelphia chromosome; BCR-ABL1; Immunohistochemistry;
The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms
Keywords: Myeloproliferative Neoplasms; DIDO; Apoptosis; JAK2V617F; BCR-ABL1;
Concomitant BCR-ABL1 positive chronic myelogenous leukemia emerging in a patient with MPL W515L associated primary myelofibrosis
Keywords: Myeloproliferative neoplasms; Chronic myelogenous leukemia; Primary myelofibrosis; BCR-ABL1; MPL W515L
A longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection system
Keywords: Automated quantitation; BCR-ABL1; chronic myelogenous leukemia; CML; monitoring; qRT-PCR;
The p16INK4A/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome
Keywords: B-cell precursor-ALL; p16INK4A/CDK4/pRb pathway; Telomerase activity; BCR-ABL1; IKAROS; Cell activation;
Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response
Keywords: BCR-ABL1; Minimal residual disease; Leukemia;
Novel BCR-ABL1 fusion identified by targeted next-generation sequencing in a patient with an atypical myeloproliferative neoplasm
Keywords: Myeloproliferative neoplasm; Chronic myeloid leukemia; BCR-ABL1; Next-generation sequencing;
Is cure of chronic myeloid leukemia in the third millennium a down to earth target (ed) or a castle in the air?
Keywords: Chronic myeloid leukemia; BCR-ABL1; Personalized medicine; Tyrosine kinase inhibitors; Genomics;
Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: Study by the Nagasaki CML Study Group
Keywords: Chronic myelogenous leukemia; BCR-ABL1; Alternative splicing; Mutation; Resistance;
Sphingosine kinase 2 prevents the nuclear translocation of sphingosine 1-phosphate receptor-2 and tyrosine 416 phosphorylated c-Src and increases estrogen receptor negative MDA-MB-231 breast cancer cell growth: The role of sphingosine 1-phosphate receptor
Keywords: Bcr-Abl1; B-cell receptor-Abelson tyrosine kinase 1; Brms1; breast carcinoma metastasis suppressor 1; cyto; cytoplasmic preparation; ER; estrogen receptor; ERM; Ezrin, Radixin, Moesin protein; ERK; extracellular signal regulated kinase; GAPDH; glyceraldeh
Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1
Keywords: SNX2-ABL1; BCR-ABL1; Acute lymphoblastic leukemia; Tyrosine kinase inhibitor; Phosphorylation
Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia
Keywords: BCR-ABL1; Kinase domain; Tyrosine kinase inhibitors; Philadelphia chromosome; Chronic myeloid leukemia; Resistance; Mutations;
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1 + cells
Keywords: CML; chronic myeloid leukemia; TK; tyrosine kinase; LSC; leukemic stem cell; APC; Adenomatous polyposis coli; GSK3; glycogen synthase kinase 3; CBY; Chibby; TCF; T cell factor; LEF; lymphoid enhancer factor; ER; endoplasmic reticulum; UPR; unfolded protei
Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia
Keywords: Chronic myeloid leukemia (CML); miR-30a; BCR-ABL1; Tumor suppressor; Cell proliferation; Cell cycle;
Simultaneous occurrence of ETV6-RUNX1 and BCR-ABL1 (e1a2) transcripts in a child with B-cell acute lymphoblastic leukemia
Keywords: Acute lymphoblastic leukemia; BCR-ABL1; e1a2; ETV6-RUNX1
BCR-ABL1 kinase facilitates localization of acetylated histones 3 and 4 on DNA double-strand breaks
Keywords: BCR-ABL1; Leukemia; Histone acetylation; DNA repair;
Nilotinib-Associated Vascular Events
Keywords: BCR-ABL1; Chronic myeloid leukemia; Nilotinib; Vascular events
Fine structure of translocation breakpoints within the major breakpoint region in BCR-ABL1-positive leukemias
Keywords: BCR-ABL1; ABL1-BCR; Chromosomal translocation; Philadelphia chromosome; Chromosomal breakpoints; Inverse PCR
Applying Cytogenetic and Molecular Information in the Clinic: Implications for the Treatment of Chronic Myeloid Leukemia
Keywords: BCR-ABL1; Dasatinib; Fluorescence in situ hybridization; Imatinib; Nilotinib
Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib
Keywords: Imatinib; Nilotinib; BCR-ABL1; CSF-1R; CML; Similarity; Adverse events; TanimotoBCR-ABL1, breakpoint cluster region-Abelson fusion protein; CML, chronic myeloid leukaemia; DDR, discoidin domain receptor; PDGFR, platelet-derived growth factor receptor; KIT
Modulators of the hedgehog signaling pathway
Keywords: Antitumor agents; Cyclopamine; Hedgehog signaling; AKT; protein kinase B; ALP; alkaline phosphatase; BCC; basal cell carcinoma; BCR-ABL1; breakpoint cluster region-Abelson murine leukemia; β-TrCP; β-transducin repeat containing protein; BMP; bone morpho
Treatment strategies for CML
Keywords: CML; imatinib; BCR-ABL1; dasatinib; nilotinib; adherence
Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones
Keywords: CML; Imatinib; Nilotinib; Bosutinib; BCR-ABL1; Clones
Megakaryocytic blast crisis as a presenting manifestation of chronic myeloid leukemia
Keywords: Chronic myeloid leukemia; Blast crisis; Acute megakaryoblastic leukemia; Target FISH; BCR-ABL1